dc.contributor.author
Kaiser, Daniel
dc.contributor.author
Otto, Natalie Maureen
dc.contributor.author
McCallion, Oliver
dc.contributor.author
Hoffmann, Henrike
dc.contributor.author
Zarrinrad, Ghazaleh
dc.contributor.author
Stein, Maik
dc.contributor.author
Beier, Carola
dc.contributor.author
Matz, Isabell
dc.contributor.author
Herschel, Marleen
dc.contributor.author
Hester, Joanna
dc.contributor.author
Moll, Guido
dc.contributor.author
Issa, Fadi
dc.contributor.author
Reinke, Petra
dc.contributor.author
Roemhild, Andy
dc.date.accessioned
2022-02-03T10:53:15Z
dc.date.available
2022-02-03T10:53:15Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/33859
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-33578
dc.description.abstract
Cell therapies have significant therapeutic potential in diverse fields including regenerative medicine, transplantation tolerance, and autoimmunity. Within these fields, regulatory T cells (Treg) have been deployed to ameliorate aberrant immune responses with great success. However, translation of the cryopreservation strategies employed for other cell therapy products, such as effector T cell therapies, to Treg therapies has been challenging. The lack of an optimized cryopreservation strategy for Treg products presents a substantial obstacle to their broader application, particularly as administration of fresh cells limits the window available for sterility and functional assessment. In this study, we aimed to develop an optimized cryopreservation strategy for our CD4+CD25+Foxp3+ Treg clinical product. We investigate the effect of synthetic or organic cryoprotectants including different concentrations of DMSO on Treg recovery, viability, phenotype, cytokine production, suppressive capacity, and in vivo survival following GMP-compliant manufacture. We additionally assess the effect of adding the extracellular cryoprotectant polyethylene glycol (PEG), or priming cellular expression of heat shock proteins as strategies to improve viability. We find that cryopreservation in serum-free freezing medium supplemented with 10% human serum albumin and 5% DMSO facilitates improved Treg recovery and functionality and supports a reduced DMSO concentration in Treg cryopreservation protocols. This strategy may be easily incorporated into clinical manufacture protocols for future studies.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
cell therapy
en
dc.subject
regulatory T cells (Tregs)
en
dc.subject
cryopreservation
en
dc.subject
freeze-thawing
en
dc.subject
freezing medium
en
dc.subject
cell recovery rate
en
dc.subject
cell viability
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Freezing Medium Containing 5% DMSO Enhances the Cell Viability and Recovery Rate After Cryopreservation of Regulatory T Cell Products ex vivo and in vivo
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
750286
dcterms.bibliographicCitation.doi
10.3389/fcell.2021.750286
dcterms.bibliographicCitation.journaltitle
Frontiers in Cell and Developmental Biology
dcterms.bibliographicCitation.originalpublishername
Frontiers Media SA
dcterms.bibliographicCitation.volume
9
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
34926446
dcterms.isPartOf.eissn
2296-634X